Search Results
HER-RAM: investigating trastuzumab, ramucirumab and paclitaxel for the second-line treatment of GC
Sara Tolaney, SABCS 2022: Adjuvant paclitaxel and trastuzumab for node-negative HER2+ breast cancer
A Phase I/II study of olaparib and ramucirumab in metastatic GC and GEJ cancer
Dr. Davis on the Role of Ramucirumab in Gastric/GEJ Cancer
ADAPT: de-escalated neoadjuvant pertuzumab+trastuzumab with or without paclitaxel in HR-/HER2+ eBC
Global Use of Second-Line Therapy in mGC
Ramucirumab Approval Expanded, Breakthrough Designation for Crizotinib, and More
Ramucirumab in NSCLC
Rebastinib and paclitaxel for advanced/metastatic ovarian cancer
Immune checkpoint inhibitors and combination strategies for patients with gastric cancer
Analyzing the Role of Second-Line Ramucirumab in HCC
Manish Shah, MD, on the role of Cyramza in the treatment of gastric and esophageal cancers
